CONFERENCE ACTIVITY Multiple conferences were attended by INOVIQ management and key scientists during the year to showcase INOVIQ’s technology and products, expand scientific and industry networks and engage with investors. Conferences included Tech Know (Aug-26, Melbourne & Sydney), AusBiotech (Oct-25, Melbourne), Thomas Ashworth CTC & Liquid Biopsy Symposium (Nov-25, Sydney), Lorne Cancer Conference (Feb-26, Lorne), Liquid Biopsy for Precision Oncology Summit (Feb-26, USA), Advanced Therapies Week (Feb-26, USA), ANZ Biologics Festival (Feb-26, Melbourne), Emergence MTPConnect & Wholesale Investor Life Sciences Day (Feb-26), Cell and Gene Therapy World Asia 2026 (Jun-26, Singapore), International Society for Cell & Gene Therapy (ISCT) ANZ (Jul-26, Melbourne) and Bioshares (Aug-26, New Zealand). EXO-NET® LICENSING ACTIVITY On 26 September 2025, INOVIQ secured an exclusive worldwide licence from The University of Queensland’s (UQ’s) commercialisation company UniQuest, to develop and commercialise novel exosomal biomarkers for the early detection of ovarian cancer. This licence builds on the Company’s successful research collaboration with UQ and internationally respected exosome expert Professor Carlos Salomon Gallo to discover, validate and develop exosomal biomarkers for early detection of ovarian cancer (ASX: 1 April 2025). INTELLECTUAL PROPERTY PORTFOLIO The Group owns or exclusively licenses a broad intellectual property (IP) portfolio of granted patents, patent applications, trade secrets and trademarks protecting INOVIQ’s technologies, products, processes and brands. The Group had 29 granted patents and 11 patents pending as at 30 June 2026, covering its Molecular NET, Exosome therapeutic, SubB2M, BARD1 and hTERT technologies and products across key jurisdictions including the United States, Europe, Asia, and Australia. Trademarks are also registered or pending for INOVIQ®, EXO-NET®, Sienna Cancer Diagnostics® and Acuris®. On 29 May 2026, the provisional patent application filed for EXO-OC proceeded to an International Patent Application, securing intellectual property rights covering various protein and RNA biomarker combinations and methods for the exosome ovarian cancer test. Review of Operations Directors’ Report Chairman’s Letter CEO’s Report Financial Report Shareholder Information 11 Annual Report 2026
RkJQdWJsaXNoZXIy MjE2NDg3